Maybe management are just being deliberately misleading in today's announcement when they say HCV and HBV partnerships will be sought after Pl/ll? Or have they just forgotten to change the slide?P26! Internal!product!pipeline!" Selected"for"technology"?t,"target"valida-on"status,"medical"need,"market"size,"etc."Strategy is to develop with partnersPre-clinical(AMD,"Tubulin,"Pain,"OPMD)"After phaseI/II(HCV,HBV)Typically will retain co-promote op-on